Published on January 11, 2010 at 6:44 AM
Inovio Biomedical Corporation (NYSE Amex: INO), a leader in DNA vaccine
design, development and delivery, announced today that it has expanded
its existing license agreement with the University of Pennsylvania,
adding exclusive worldwide licenses for technology and intellectual
property for novel DNA vaccines against pandemic influenza, Chikungunya,
and foot-and-mouth disease. The amendment also encompasses new chemokine
and cytokine molecular adjuvant technologies. The technology was
developed in the University of Pennsylvania laboratory of Professor
David B. Weiner, a pioneer in the field of DNA vaccines, and chairman of
Inovio’s scientific advisory board.
“Our DNA vaccine
technology offers the potential to prevent and/or treat a broad array of
cancers and infectious diseases, and has achieved compelling preclinical
and initial clinical results. This new intellectual property from an
eminent DNA vaccine research laboratory broadens our opportunities to
pursue important new infectious diseases.”
Dr. J. Joseph Kim, president and CEO, stated, “Our DNA vaccine
technology offers the potential to prevent and/or treat a broad array of
cancers and infectious diseases, and has achieved compelling preclinical
and initial clinical results. This new intellectual property from an
eminent DNA vaccine research laboratory broadens our opportunities to
pursue important new infectious diseases.”
Under the terms of the original license agreement completed in 2007, the
Company obtained exclusive worldwide rights to develop multiple DNA
plasmids and constructs with the potential to treat and/or prevent HIV,
HCV, HPV and influenza and included molecular adjuvants. These prior and
most recent agreements and amendments provide for royalty payments,
based on future sales, to the University of Pennsylvania.
http://www.inovio.com/